Secondary Prevention of Atrial Fibrillation (Impact of Renin-Angiotensin-Aldosterone System Inhibition)
Phase of Trial: Phase IV
Latest Information Update: 27 Jan 2016
At a glance
- Drugs Losartan (Primary)
- Indications Atrial fibrillation
- Focus Pharmacogenomic; Therapeutic Use
- 04 Jan 2016 Status changed from active, no longer recruiting to discontinued, according to ClinicalTrials.gov record.
- 21 Nov 2011 Planned End Date changed from 1 Dec 2015 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 21 Nov 2011 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.